Natixis Advisors L.P. Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Natixis Advisors L.P. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 279,620 shares of the biopharmaceutical company's stock after acquiring an additional 36,711 shares during the period. Natixis Advisors L.P.'s holdings in Gilead Sciences were worth $22,652,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Clearbridge Investments LLC raised its stake in Gilead Sciences by 179.0% in the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company's stock valued at $340,526,000 after buying an additional 2,915,141 shares in the last quarter. abrdn plc increased its position in shares of Gilead Sciences by 89.0% during the fourth quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company's stock worth $304,930,000 after purchasing an additional 1,772,887 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $133,584,000. AEGON ASSET MANAGEMENT UK Plc acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $63,971,000. Finally, Van ECK Associates Corp increased its position in shares of Gilead Sciences by 18.3% during the third quarter. Van ECK Associates Corp now owns 4,534,839 shares of the biopharmaceutical company's stock worth $339,841,000 after purchasing an additional 702,342 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Royal Bank of Canada cut their target price on Gilead Sciences from $76.00 to $74.00 and set a "sector perform" rating on the stock in a research report on Friday, April 26th. HSBC upgraded Gilead Sciences from a "reduce" rating to a "hold" rating and set a $69.00 target price on the stock in a research report on Wednesday, April 24th. Truist Financial downgraded Gilead Sciences from a "buy" rating to a "hold" rating and decreased their target price for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Maxim Group reduced their price objective on Gilead Sciences from $90.00 to $85.00 and set a "buy" rating on the stock in a research report on Wednesday, May 1st. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Friday, April 26th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $83.69.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded up $0.76 on Monday, reaching $65.54. 7,186,870 shares of the company were exchanged, compared to its average volume of 7,456,667. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The company's 50-day moving average is $70.40 and its two-hundred day moving average is $75.68. The firm has a market cap of $81.60 billion, a price-to-earnings ratio of 182.06, a P/E/G ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a 1-year low of $64.33 and a 1-year high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts' consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analysts' expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business's quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.37 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.70%. The ex-dividend date is Friday, June 14th. Gilead Sciences's dividend payout ratio is currently 855.56%.

Insider Activity at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.29% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.